CG Oncology, Inc. (CGON) stock
Close on Nov 11, 2026Market cap $6.44BP/E –Yield –
CG Oncology, Inc. grew revenue 183.6% to $6.17M over the twelve months to Sep 30, 2026. Free cash flow was -$189.17M. At the latest close the market valued the company at $6.44B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $6.44B
- P/E ratio
- –
- Price to sales
- 1043.82
- Price to book
- 6.49
- Dividend yield
- –
- Free cash flow yield
- -2.94%
Fundamentals
- Revenue
- $6.17M
- Net income
- -$237.46M
- EPS, diluted
- -$2.77
- Free cash flow
- -$189.17M
- Book value per share
- $11.15
- Diluted shares
- 89M
Trading
- Next earnings
- Feb 26, 2027 (estimated, before the open)
- Previous close
- $72.64
- Open
- $73.21
- Day's range
- $72.49 – $75.19
- Volume
- 890,173
- Average volume (20 days)
- 1,091,225
- Index membership
- Russell 2000 (since Mar 2024), Russell 3000 (since Feb 2024)
- Beta (5 years)
- 1.41
- 52-week range
- $35.80 – $80.97
- RSI (14 days)
- 60.3
- Volatility (1 year)
- 58.2%
- Relative volume
- 0.95×
- WACC
- 11.9%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CGON | S&P 500 | Difference | CGON per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +13.8% | -2.4% | +16.2 pts | ||
| 3 months | -5.7% | -1.2% | −4.6 pts | ||
| Year to date | +74.9% | +12.3% | +62.6 pts | ||
| 1 year | +86.9% | +12.4% | +74.5 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CG Oncology filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Update
About CG Oncology
Biological Products, (No Diagnostic Substances)
CG Oncology is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing cretostimogene grenadenorepvec, an oncolytic immunotherapy designed for bladder cancer. The investigational candidate features a dual mechanism of action that eliminates cancer cells through selective replication and prompts an anti-tumor immune response. Operating in the biopharmaceutical sector, the company focuses on bladder cancer therapeutics. Its target patient populations include individuals afflicted with high-risk and intermediate-risk non-muscle invasive bladder cancer, such as patients who are BCG-unresponsive, BCG-exposed, or BCG-naïve.
Company profile, executives and historyCG Oncology stock: common questions
What is CG Oncology's stock price?
CGON closed at $72.61 on Nov 11, 2026, down 0.04% on the day. Over the past 52 weeks it traded between $35.80 and $80.97.
What is CG Oncology's market cap?
CG Oncology was worth $6.44B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CGON's P/E ratio?
CG Oncology lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.77), so it has no meaningful P/E ratio.
How much revenue does CG Oncology make?
CG Oncology reported revenue of $6.17M for the twelve months to Sep 30, 2026, up 183.6% from a year earlier.
Does CG Oncology pay a dividend?
No. CG Oncology has not paid a cash dividend over the last twelve months.
When does CG Oncology report earnings next?
CG Oncology is expected to report Q4 FY2026 results on Feb 26, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CGON stock performed over the past year?
Including dividends, CGON returned +86.9% over the past year, against +12.4% for the S&P 500.
How many CGON shares are sold short?
9M shares were sold short at the latest FINRA report, 12.57% of the float, or 11.0 days of average trading volume.
Who are CG Oncology's competitors?
Companies most similar to CG Oncology by business, industry and size include TCRX, CRBU, ATRA, MOLN, RLAY.
See a number that looks wrong?